APP and Alzheimer disease: For instance, prolonged treatment (>5 months) with the AD-targeted Aβ1-6A2VTAT(D) peptide increased the amyloid burden due to a shift in APP processing towards the amyloidogenic pathway, which is attributed to the D-isomer TAT sequence of the construct [154].